Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a common type of malignant tumors in urinary system. Evaluating the prognostic outcome at the time of initial diagnosis is essential for patients. Autophagy is known to play a significant role in tumors. Here, we attempted to construct an autophagy-related prognostic risk signature based on the expression profile of autophagy-related genes (ARGs) for predicting the long-term outcome and effect of precise treatments for ccRCC patients.Methods: We obtained the expression profile of ccRCC from the cancer genome atlas (TCGA) database and extract the portion of ARGs. We conducted differentially expressed analysis on ARGs and then performed enrichment analyses to confirm the anomalous autophagy-related biological functions. Then, we performed univariate Cox regression to screen out overall survival (OS)-related ARGs. With these genes, we established an autophagy-related risk signature by least absolute shrinkage and selection operator (LASSO) Cox regression. We validated the reliability of the risk signature with receiver operating characteristic (ROC) analysis, survival analysis, clinic correlation analysis, and Cox regression. Then we analyzed the function of each gene in the signature by single-gene gene set enrichment analysis (GSEA). Finally, we analyzed the correlation between our risk score and expression level of several targets of immunotherapy and targeted therapy.Results: We established a seven-gene prognostic risk signature, according to which we could divide patients into high or low risk groups and predict their outcomes. ROC analysis and survival analysis validated the reliability of the signature. Clinic correlation analysis found that the risk group is significantly correlated with severity of ccRCC. Multivariate Cox regression revealed that the risk score could act as an independent predictor for the prognosis of ccRCC patients. Correlation analysis between risk score and targets of precise treatments showed that our risk signature could predict the effects of precise treatment powerfully.Conclusion: Our study provided a brand new autophagy-related seven-gene prognostic risk signature, which could perform as a prognostic indicator for ccRCC. Meanwhile, our study provides a novel sight to understand the role of autophagy and suggest therapeutic strategies in the category of precise treatment in ccRCC.

Highlights

  • Renal cell carcinoma (RCC) is one of the most common types of malignant tumors, which accounts for ∼2% of all kind of cancer diagnoses and deaths worldwide

  • We evaluated if all these factors are risk factors for worse outcomes by univariate Cox regression analysis, and further determined if the risk score calculated by our risk signature could be utilized for predicting the prognosis of Clear cell renal cell carcinoma (ccRCC) patients independently

  • According to the screening criteria of differentially expressed genes (DEGs), 89 of the 231 autophagy-related genes (ARGs) showed significant alterations of expression levels in ccRCC compared with normal control, including 61 up-regulated and 27 down-regulated genes, respectively

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is one of the most common types of malignant tumors, which accounts for ∼2% of all kind of cancer diagnoses and deaths worldwide. Clear cell renal cell carcinoma (ccRCC) is the main subtype of RCC and occupies about 80–90% of all [2, 3]. In clinical work, it is a vital and hard task to estimate the longterm outcome of tumor patients and make therapeutic decisions . TNM staging is a classical method for assessing the prognostic outcome of tumor patients and has been employing for almost 100 years. We attempted to construct an autophagy-related prognostic risk signature based on the expression profile of autophagy-related genes (ARGs) for predicting the long-term outcome and effect of precise treatments for ccRCC patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call